Navigation Neurocentre Magendie - U1215 par Auteur "LABAUGE, Pierre"
-
Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.
SABATHÉ, Camille; CASEY, Romain; VUKUSIC, Sandra ...(Multiple Sclerosis Journal. vol. 29, n° 2, pp. 236-247, 2023-02-01)Article de revue -
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
FISSOLO, Nicolas; PIGNOLET, Beatrice; RIO, Jordi ...(Neurology. vol. 8, n° 4, 2021-04-26)Article de revueLibre accès -
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal
ROLLOT, Fabien; COUTURIER, Justine; CASEY, Romain ...(Neurotherapeutics. vol. 19, n° 2, pp. 476-490, 2022-03)Article de revueLibre accès -
Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study
WILSON, Sarah; CALOCER, Floriane; ROLLOT, Fabien ...(The Lancet Regional Health - Europe. vol. 24, 2023)Article de revueLibre accès -
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.
GAVOILLE, Antoine; ROLLOT, Fabien; CASEY, Romain ...(Neurology. vol. 100, n° 12, pp. e1296-e1308, 2023-03-21)Article de revueLibre accès -
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis
GARCIA, Alexandra; DUGAST, Emilie; SHAH, Sita ...(Neurology(R) neuroimmunology & neuroinflammation. vol. 10, n° 3, 2023-02-21)Article de revueLibre accès -
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification among Natalizumab Users in France
VUKUSIC, Sandra; ROLLOT, Fabien; CASEY, Romain ...(JAMA Neurology. vol. 77, n° 1, pp. 94-102, 2020-01-01)Article de revueLibre accès -
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis
BENALLEGUE, Nail; ROLLOT, Fabien; WIERTLEWSKI, Sandrine ...(JAMA neurology. vol. 81, n° 3, pp. 273-282, 2024-03-01)Article de revueLibre accès